Catalyst Wire Dossier Catalyst Wire Dossier

ALXN2050 60 mg tablet

ALXN2050 · Alexion Pharmaceuticals, Inc.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for ALXN2050 60 mg tablet, covering 2025-02-14 to 2025-02-14. Get the full timeline:

Most recent: Clinical Trial Update: Bioequivalence Between 180 mg and 60 mg ALXN2050 Tablets and Food Effect on ALXN2050 Pharmacokinetics [Phase 1]

See pricing